129299-72-5

Upstream product

• 40133-76-4 8,9-dihydro-10-methyl-pyrido[1,2-a]indol-6(7H)-on 
• 155795-83-8 4-chloromethyl-5-methyl-1-(4-methylbenzenesulphonyl)-imidazole 
• 138476-55-8 8,9-dihydro-7-<(hydroxy)<5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl>methyl>-10-methylpyrido<1,2-a>indol-6(7H)-one 
• 129299-71-4 8,9-dihydro-10-methyl-7-[(5-methyl-1-trityl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]-indol-6(7H)-one 
• 7285-11-2 chloroform methanol 
• 129299-69-0 7-[(acetoxy)-(5-methyl-1-trityl-1H-imidazol-4-yl)methyl]-8,9-dihydro-10-methylpyrido[1,2-a]indol-6(7H)-one 
• 113140-81-1 5-methyl-1-(triphenylmethyl)-1H-imidazole-4-carboxaldehyde 
• 138476-75-2 (+/-)-8,9-dihydro-7-<(5-methyl-1H-imidazol-4-yl)methyl>pyrido<1,2-a>indol-6(7H)-one 
• 129299-94-1 7-[(acetoxy)-(5-methyl-1-trityl-1H-imidazol-4-yl)methyl]-8,9-dihydropyrido[1,2-a]indol-6(7H)-one 
• 138476-60-5 8,9-dihydro-7-[(hydroxy)-(5-methyl-1-trityl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]-indol-6(7H)-one 
• 166324-47-6 8,9-dihydro-7-<<5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl>methylene>pyrido<1,2-a>indol-6(7H)-one 
• 91486-91-8 <2-(2,6-dioxopiperidin-1-yl)phenylmethyl>triphenylphosphonium bromide 
• 91486-93-0 6,7,8,9-tetrahydropyrido[1,2-a]indol-6-one 
• 138476-77-4 (+/-)-8,9-dihydro-10-(dimethylaminomethyl)-7-<(5-methyl-1H-imidazol-4-yl)methyl>pyrido<1,2-a>indol-6(7H)-one 

Relevant academic research and scientific papers

Processes for producing pyridoindole derivatives

PCT No. PCT/JP96/02692 Sec. 371 Date Apr. 21, 1998 Sec. 102(e) Date Apr. 21, 1998 PCT Filed Sep. 18, 1996 PCT Pub. No. WO97/11074 PCT Pub. Date Mar. 27, 1997A process for producing pyridiondole derivatives represented by general formula (III) or their sal

New 5-HT3 (serotonin-3) receptor antagonists. III. An efficient synthesis of carbon 14-labeled (+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4- yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride (FK 1052).

(+)-8,9-Dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4- yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride (FK 1052, 1) is a highly potent 5-HT3 (serotonin-3) receptor antagonist. For the study of the metabolism and disposition of FK 1052 (1), we synthesized carbon 14-labeled FK 1052 in three steps from 10-demethyl FK 1052 (8). The Mannich reaction and subsequent hydrogenolysis of the dimethylaminomethyl group enabled the efficient introduction of one carbon atom at the 10-position of the pyrido[1,2-a]indol-6,(7H)-one ring. The Mannich reaction of (+)-8,9-dihydro-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2- ]indol-6(7H)-one (8) with [14C]paraformaldehyde and dimethylamine hydrochloride gave the [14C]-10-dimethylaminomethyl compound (20). Subsequent hydrogenolysis of 20 with palladium on carbon and ammonium formate, followed by recrystallization of the salt with (+)-di-p-toluoyl-D-tartaric acid, gave [14C]FK 1052 with a radiochemical purity of 99.4% and an enantiomeric excess of more than 97%.

New 5-HT3 (serotonin-3) receptor antagonists, I. Synthesis and structure-activity relationships of pyrido[1,2-a]indoles

A series of pyrido[1,2-a]indol-6(7H)-ones was prepared and evaluated for 5-HT3 receptor antagonist activity. The structural requirements for the 5-HT3 receptor antagonist have been defined as an aromatic moiety, a basic nitrogen, and

PYRIDOINDOLE DERIVATIVES AND PROCESSES FOR PREPARATION THEREOF

The invention relates to compounds for treatment of nausea and vomiting, of the formula STR1 wherein R 1 is hydrogen, lower alkyl, lower alkenyl or N,N-di(lower)alkylaminomethyl,R. sup.2 is hydrogen, lower alkyl or halogen,R 3 is imidazolyl or

Pyridoindole derivatives and processes for preparation thereof

Compounds of the formula: STR1 wherein R 1 is hydrogen, lower alkyl or lower alkenyl, R 2 is hydrogen, lower alkyl, or halogen, R 3 is imidazolyl or pyridyl, each of which may have suitable substituents, and R 4 is hydrogen, lower alkyl, lower alkenyl or